BioNotebook: One deal ends for Vanda, Novartis; five new agreements begin
This article was originally published in Scrip
Executive Summary
Vanda, Novartis settle Fanapt dispute; Genentech, Phylogica partner on antibiotics; Janssen licenses Sevion antibody platform; Pfizer accesses Philogen antibodies; Tiziana licenses Novimmune asset; and EpiVax applies Novozymes technology.